Embecta Corp.

NASDAQ:EMBC

Drug Manufacturers - Specialty & Generic

Healthcare
$6.09 +0.65%

+$0.02 today

Market cap
$345.06M
Beta
0.81
P/E (TTM)
1.6
EPS (TTM)
$1.92
Dividend yield
14.79%
52W Low $2.77High $15.55

Volume 0.72M

Average 1.95M

EMBC Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Embecta Corp.NASDAQ: EMBC

Net Income · Q2 FY2026 · quarter ended Mar 2026

Net income turns negative

Q2 FY2026 net income was -$4.1M, compared with $23.5M a year earlier. Trailing-twelve-month net income was $111.9M. Over 3 fiscal years it compounded at -24.7% a year.

Context

  • Net income amounted to 8.8% of revenue in FY2025, up 1.9 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of $107.46M (+12.6%) for the fiscal year ending Sep 2026, a slowdown from the +21.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.1M-109.3% QoQ
Last fiscal yearSep 2025
$95.4M+21.8% YoY
LTMMar 2026
$111.9M+111.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-117.4%-65.8%+51.6 pp
1 year+21.8%+12.6%-9.2 pp
3-year CAGR-24.7%+3.9%+28.6 pp
5-year CAGR+13.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
95.4M USD
Year-over-year change
+21.8%
4-year CAGR
-30.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How EMBC compares with its peers on the latest reported figures

  • EMBC's LTM Mar 2026 net income of $111.9M is the 5th largest of the 11 companies compared; the peer median is $94.61M.
  • Its year-over-year change of +111.9% is the 3rd highest of 11, against a peer median of +5.9%.
  • Net income amounts to 10.7% of revenue for EMBC, versus a peer median of 46.6%.
EMBC Competitors Peer median
Net Income for EMBC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EVHEvolent Health, Inc.LTM Mar 2026$527.72M +384.3%+211.5%27.9%
VIRVir Biotechnology, Inc.LTM Mar 2026$442.72M -23.4%—676.0%
MYGNMyriad Genetics, Inc.LTM Mar 2026$399.9M +294.4%+48.4%48.2%
PRMEPrime Medicine, Inc.LTM Mar 2026$198.37M -1.8%+18.2%4917.6%
EMBCEmbecta Corp.LTM Mar 2026$111.9M +111.9%-24.7%10.7%
CDNACareDx, IncLTM Jun 2026$111.01M +90.9%-34.7%24.2%
PSNLPersonalis, Inc.LTM Mar 2026$95.55M +13.7%-10.5%148.1%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$93.67M -68.6%—44.9%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$68.91M +27.1%+15.5%137.1%
SIGASIGA Technologies, Inc.LTM Mar 2026$20.23M -58.3%-11.8%21.6%
EBSEmergent BioSolutions Inc.LTM Mar 2026$8.6M -93.5%—1.3%
Peer median (excluding EMBC) $94.61M+5.9%+15.5%46.6%

Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income415M223.6M70.4M78.3M95.4M
Depreciation & Amortization38M31.7M32.6M36.2M40.7M
Deferred Income Tax(2M)(26.5M)14.3M(70.6M)17.6M
Stock-Based Compensation12.8M18.7M21.5M26.3M31.6M
Change in Working Capital(32M)92.4M(80M)(47.7M)(23.7M)
Accounts Receivables(32M)122.7M7M(174.7M)44.2M
Inventory(18M)(23.4M)(28.8M)(16.5M)(6.1M)
Accounts Payables30M73.3M7.9M60M(68.9M)
Other Working Capital(12M)(80.2M)(66.1M)83.5M7.1M
Other Non-Cash Items24.2M72.3M8.9M13.2M30.1M
Operating Cash Flow456M412.2M67.7M35.7M191.7M
Capital Expenditures(39M)(24M)(26.5M)(15.8M)(9.3M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(39M)(24M)(26.5M)(15.8M)(9.3M)
Debt Repayment01.44B(10.7M)(35.9M)(186M)
Common Stock Issued00000
Common Stock Repurchased00(3.6M)(3M)(5.7M)
Dividends Paid0(8.6M)(34.4M)(34.5M)(35M)
Other Financing Activities(417M)(1.48B)000
Financing Cash Flow(417M)(48M)(48.7M)(73.4M)(226.7M)
Effect of Forex Changes0(9.3M)3.1M1.2M(1.3M)
Net Change in Cash0330.9M(4.4M)(52.3M)(45.6M)
Free Cash Flow417M388.2M41.2M19.9M182.4M

Embecta Corp.

NASDAQ:EMBC

Intrinsic Alpha fair value

Locked

Current Price

$6.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.